Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape

Nat Rev Drug Discov. 2022 Jul;21(7):482-483. doi: 10.1038/d41573-022-00030-4.
No abstract available

MeSH terms

  • B7-H1 Antigen*
  • Clinical Trials as Topic
  • Humans
  • Immune Checkpoint Inhibitors
  • Programmed Cell Death 1 Receptor*

Substances

  • B7-H1 Antigen
  • Immune Checkpoint Inhibitors
  • Programmed Cell Death 1 Receptor